How Candida albicans biofilms use tiny vesicles to resist antifungal drugs
Vesicle-mediated drug resistance of Candida albicans biofilm
This work looks at whether tiny particles released by Candida albicans biofilms help them resist antifungal drugs, aiming to benefit people with device-related fungal infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11177812 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are examining the tiny extracellular vesicles that Candida biofilms release to find what cargo they carry and how that cargo helps the biofilm survive treatment. They grow biofilms in the lab, add or remove vesicles in controlled tests, study mutant fungal strains with altered vesicle production, and test a new antifungal called turbinmicin to see if blocking vesicle production restores drug sensitivity. The team uses genetic and biochemical methods to map the pathways that control vesicle formation and matrix production so they can identify targets for new therapies. Results will guide whether blocking vesicle pathways could make existing antifungals work better against stubborn device-related infections.
Who could benefit from this research
Good fit: People with or at high risk for Candida albicans biofilm infections on medical devices (such as catheters, prosthetic implants, or recurrent bloodstream infections) would be the most relevant group for future clinical follow-up from this research.
Not a fit: Patients with non-Candida fungal infections, simple superficial yeast infections, or infections already cleared by standard topical treatments are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could lead to therapies that make drug-resistant Candida biofilms on medical devices responsive to current antifungal drugs.
How similar studies have performed: Previous lab studies have shown that extracellular vesicles carry matrix components linked to resistance, ESCRT pathway genes affect vesicle production, and the antifungal turbinmicin can block vesicle and matrix production in preclinical tests, but clinical benefit has not yet been demonstrated.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Andes, David R — University of Wisconsin-Madison
- Study coordinator: Andes, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.